NGY-091

Despite the recent FDA approval of Abraxane (nab-paclitaxel) and Atezolizumab (anti-PD-L1) for a subset of Triple-Negative Breast Cancer (TNBC) patients, there remains an unmet need to develop novel therapeutic strategies to effectively combat this disease. Therefore, such a broader effect on multiple immune cells by NGY-B leads to overall immune activation in the TME. Our pre-clinical work shows that NGY-B intervenes two key hallmarks of caner; metabolism and immunity, providing us a novel therapeutic modality to combat TNBC.

Supporting this premise, we also found that NGY-B treated cells showed a decrease in PD-L1, B7-H3, and B7-H4 expression. Overall, our results indicate that NGY-B inhibits melanoma by targeting metabolic symbiosis and activating antitumor immune response mechanisms.